Protara Therapeutics, Inc. (NASDAQ:TARA) Insider Jacqueline Zummo Sells 21,224 Shares of Stock

Protara Therapeutics, Inc. (NASDAQ:TARA) insider Jacqueline Zummo sold 21,224 shares of the business’s stock in a transaction that occurred on Wednesday, March 26th. The shares were sold at an average price of $4.53, for a total transaction of $96,144.72. Following the transaction, the insider now directly owns 98,861 shares of the company’s stock, valued at approximately $447,840.33. This represents a 17.67 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Protara Therapeutics Trading Up 0.9 %

NASDAQ:TARA opened at $4.58 on Friday. The stock has a market capitalization of $168.39 million, a P/E ratio of -1.62 and a beta of 1.69. The stock has a 50-day moving average price of $4.27 and a 200 day moving average price of $3.66. Protara Therapeutics, Inc. has a 12-month low of $1.60 and a 12-month high of $10.48.

Protara Therapeutics (NASDAQ:TARA) last issued its quarterly earnings results on Wednesday, March 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.09. On average, research analysts predict that Protara Therapeutics, Inc. will post -3.32 earnings per share for the current fiscal year.

Institutional Trading of Protara Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC increased its holdings in Protara Therapeutics by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 179,593 shares of the company’s stock worth $948,000 after buying an additional 9,553 shares during the period. Commonwealth Equity Services LLC grew its stake in Protara Therapeutics by 90.4% in the 4th quarter. Commonwealth Equity Services LLC now owns 37,000 shares of the company’s stock valued at $195,000 after acquiring an additional 17,572 shares during the period. HBK Investments L P acquired a new stake in Protara Therapeutics in the 4th quarter worth about $106,000. Squarepoint Ops LLC purchased a new stake in shares of Protara Therapeutics during the fourth quarter worth approximately $110,000. Finally, Dimensional Fund Advisors LP acquired a new stake in shares of Protara Therapeutics in the fourth quarter valued at about $111,000. Hedge funds and other institutional investors own 38.13% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and set a $23.00 target price on shares of Protara Therapeutics in a report on Thursday, March 6th. Cantor Fitzgerald assumed coverage on shares of Protara Therapeutics in a report on Friday, March 14th. They issued an “overweight” rating for the company. Guggenheim restated a “buy” rating and set a $20.00 price target on shares of Protara Therapeutics in a research report on Friday, December 6th. Finally, Lifesci Capital assumed coverage on shares of Protara Therapeutics in a report on Tuesday, March 11th. They issued an “outperform” rating and a $22.00 price objective on the stock. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $22.50.

About Protara Therapeutics

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.